OBJECTIVE: Compare colonic distension and perceived burden of CT-colonography between participants receiving hyoscine butylbromide (buscopan) and glucagon hydrochloride as bowel relaxant. MATERIALS AND METHODS: Data were collected within a screening trial. Participants received 20mg buscopan intravenously or 1mg of glucagon intravenously (if buscopan contra-indicated). Colon distension per segment was assessed using a 4-point scale (prone and supine). Data on perceived burden of CT-colonography were collected using a questionnaire two weeks after the examination. Outcome measures between groups were compared using propensity score matching. We used a stratified Wilcoxon-Mann-Whitney test statistic for quantitative and Cochran-Mantel-Haenszel statistics for categorical variables. RESULTS: 541 participants were included: 336 (62%) received buscopan and 205 received glucagon. All buscopan recipients had an adequately distended colon, compared to 96% in the glucagon group (RR 7.31, 95% CI: 1.61-33.28). More glucagon recipients scored the insufflation as rather or extremely burdensome (25% vs. 16%; overall mean score 2.7 vs. 2.4; p<0.001) and more found the entire CT-colonography rather or extremely burdensome (14% vs. 7%; 2.2 vs. 1.9; p=0.001). Most frequently reported side effects were a dry mouth in the buscopan group (15%) and nausea in the glucagon group (13%). CONCLUSION: Compared to glucagon, premedication with buscopan results in significantly more adequately distended colons and a less burdensome procedure. When buscopan can be used, it is the preferred bowel relaxant.
OBJECTIVE: Compare colonic distension and perceived burden of CT-colonography between participants receiving hyoscine butylbromide (buscopan) and glucagon hydrochloride as bowel relaxant. MATERIALS AND METHODS: Data were collected within a screening trial. Participants received 20mg buscopan intravenously or 1mg of glucagon intravenously (if buscopan contra-indicated). Colon distension per segment was assessed using a 4-point scale (prone and supine). Data on perceived burden of CT-colonography were collected using a questionnaire two weeks after the examination. Outcome measures between groups were compared using propensity score matching. We used a stratified Wilcoxon-Mann-Whitney test statistic for quantitative and Cochran-Mantel-Haenszel statistics for categorical variables. RESULTS: 541 participants were included: 336 (62%) received buscopan and 205 received glucagon. All buscopan recipients had an adequately distended colon, compared to 96% in the glucagon group (RR 7.31, 95% CI: 1.61-33.28). More glucagon recipients scored the insufflation as rather or extremely burdensome (25% vs. 16%; overall mean score 2.7 vs. 2.4; p<0.001) and more found the entire CT-colonography rather or extremely burdensome (14% vs. 7%; 2.2 vs. 1.9; p=0.001). Most frequently reported side effects were a dry mouth in the buscopan group (15%) and nausea in the glucagon group (13%). CONCLUSION: Compared to glucagon, premedication with buscopan results in significantly more adequately distended colons and a less burdensome procedure. When buscopan can be used, it is the preferred bowel relaxant.
Authors: Charlotte J Tutein Nolthenius; Thierry N Boellaard; Margriet C de Haan; C Yung Nio; Maarten G J Thomeer; Shandra Bipat; Alexander D Montauban van Swijndregt; Marc J van de Vijver; Katharina Biermann; Ernst J Kuipers; Evelien Dekker; Jaap Stoker Journal: Am J Gastroenterol Date: 2015-10-20 Impact factor: 10.864
Authors: Thierry N Boellaard; Marije P van der Paardt; Markus W Hollmann; Susanne Eberl; Jan Peringa; Lex J Schouten; Giedre Kavaliauskiene; Jurgen H Runge; Jeroen A W Tielbeek; Jaap Stoker Journal: BMC Gastroenterol Date: 2013-05-25 Impact factor: 3.067
Authors: Kiran C Mahabier; Esther M M Van Lieshout; Hugo W Bolhuis; P Koen Bos; Maarten Wga Bronkhorst; Milko M M Bruijninckx; Jeroen De Haan; Axel R Deenik; Boudewijn J Dwars; Martin G Eversdijk; J Carel Goslings; Robert Haverlag; Martin J Heetveld; Albert J H Kerver; Karel A Kolkman; Peter A Leenhouts; Sven A G Meylaerts; Ron Onstenk; Martijn Poeze; Rudolf W Poolman; Bas J Punt; W Herbert Roerdink; Gert R Roukema; Jan Bernard Sintenie; Nicolaj M R Soesman; Andras K F Tanka; Edgar J T Ten Holder; Maarten Van der Elst; Frank H W M Van der Heijden; Frits M Van der Linden; Peer Van der Zwaal; Jan P Van Dijk; Hans-Peter W Van Jonbergen; Egbert J M M Verleisdonk; Jos P A M Vroemen; Marco Waleboer; Philippe Wittich; Wietse P Zuidema; Suzanne Polinder; Michael H J Verhofstad; Dennis Den Hartog Journal: BMC Musculoskelet Disord Date: 2014-02-11 Impact factor: 2.362